Patents for A61P 35 - Antineoplastic agents (221,099)
07/2003
07/16/2003CN1114410C Product of heat treatment of uronic acid, food, drink and drug containing the product
07/16/2003CN1114403C Vitronectin receptor antagonists
07/15/2003US6593493 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes
07/15/2003US6593482 Methods for preparing new taxoids and pharmaceutical compositions containing them
07/15/2003US6593466 Guanidinium functionalized nucleotides and precursors thereof
07/15/2003US6593374 Such as 3-(3'4'5'-trimethoxybenzoyl)-2-(3'benzylphosphate 4'methoxyphenyl)-6-methoxybenzo(b)thiophene; functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates useful as antitumor agents
07/15/2003US6593359 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
07/15/2003US6593357 Treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
07/15/2003US6593356 The present invention relates to the synthesis of a new class of indeno(1,2-c)pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and the
07/15/2003US6593353 p53 inhibitors and therapeutic use of the same
07/15/2003US6593352 2-phenylalkylaminobenzoic acid containing substituted benzylsufamoyl group; useful for treating cardiovascular disorders, and for preserving or storing a transplant for surgery
07/15/2003US6593351 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
07/15/2003US6593347 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
07/15/2003US6593344 These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases
07/15/2003US6593342 Pharmaceutical compositions comprising 2-quinolones
07/15/2003US6593334 Camptothecin-taxoid conjugates as antimitotic and antitumor agents
07/15/2003US6593333 Substituted anilino-quinazoline (or quinoline) compounds and use thereof
07/15/2003US6593327 Compounds and compositions as protease inhibitors
07/15/2003US6593326 Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man.
07/15/2003US6593322 Compounds and methods for modulation of estrogen receptors
07/15/2003US6593305 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
07/15/2003US6593303 Anti-tumor synergetic composition
07/15/2003US6593292 Amidine and/or guanidine substituted peptoid and drug conjugates for drug delivery across endo/epithelial tissue
07/15/2003US6593291 Inhibition of endothelial cell proliferation inhibits neovascularization
07/15/2003US6593132 Nucleotide sequences coding polypeptide for use in the treatment of cancer
07/15/2003US6593108 Nucleic acid molecule encoding a melanin-concentrating hormone receptor 2 polypeptide
07/15/2003US6592911 (−)-Olivil as antioxidant which is obtained from a new natural source namely Stereospermum personatum
07/15/2003US6592901 Highly compressible ethylcellulose for tableting
07/15/2003US6592894 Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
07/15/2003US6592868 Produced by hybridoma having ATCC Accession Number HB 10916
07/15/2003US6592862 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
07/15/2003US6592843 Liposome mixture containing chelator solution and alpha particle emitting radionuclides; cancer therapy
07/15/2003CA2238465C Triaromatic compounds, compositions containing them and uses
07/15/2003CA2218766C Bicyclic-aromatic compounds
07/10/2003WO2003056012A1 A system for stable expression of sirnas in mammalian cells
07/10/2003WO2003055993A1 Composition of antibody specifically binding to cd20
07/10/2003WO2003055917A2 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
07/10/2003WO2003055915A2 Human netrin receptor and uses thereof
07/10/2003WO2003055913A2 Secreted protein
07/10/2003WO2003055912A2 Secreted proteins
07/10/2003WO2003055911A2 Cystine-knot fold protein
07/10/2003WO2003055910A1 Beta-amyloid binding factors and inhibitors thereof
07/10/2003WO2003055887A1 Conjugated porphyrin, chlorin or bacteriochlorin chromophore
07/10/2003WO2003055884A1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
07/10/2003WO2003055882A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors
07/10/2003WO2003055876A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
07/10/2003WO2003055875A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055874A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055868A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors
07/10/2003WO2003055867A1 Biphenylmethyl-thiazolidinediones and analogues and their use as ppar-gamma activators
07/10/2003WO2003055865A1 Quinazolinone derivative
07/10/2003WO2003055864A1 Long chain fatty alcohol substituents in antineoplastic agents
07/10/2003WO2003055863A1 Novel alkansulfonamides as endothelin antagonists
07/10/2003WO2003055861A1 Benzocyclodecane derivatives with antitumor activity
07/10/2003WO2003055860A1 3,4-diarylpyrazoles and their use in the therapy of cancer
07/10/2003WO2003055847A1 Carboxylic acid derivative
07/10/2003WO2003055527A2 Immunoconjugates useful for treatment of tumours
07/10/2003WO2003055522A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
07/10/2003WO2003055520A1 Delivery of neutron capture elements for neutron capture therapy
07/10/2003WO2003055515A1 Individualized anti-cancer antibodies
07/10/2003WO2003055506A1 Preventives/remedies for cancer
07/10/2003WO2003055501A1 The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
07/10/2003WO2003055495A1 ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17β-ESTRADIOL-3-LOWER ALKANOATE, METHOD OF ADMINISTERING THE SAME AND PROCESS OF PREPARATION
07/10/2003WO2003055493A1 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
07/10/2003WO2003055491A1 Substituted quinazoline derivatives as inhibitors of aurora kinases
07/10/2003WO2003055485A1 Dosing regimen for ppar-gamma activators
07/10/2003WO2003055481A1 Organ fibrosis inhibitors
07/10/2003WO2003055470A1 Novel microsphere and method for production thereof
07/10/2003WO2003055469A1 Improved polymer-lipid delivery vehicles
07/10/2003WO2003055447A2 Heterocyclic acridone inhibitors of impdh enzyme
07/10/2003WO2003050119A3 Urea substituted imidazopyridines
07/10/2003WO2003041653A3 Cytotoxic agents
07/10/2003WO2003039437A3 Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
07/10/2003WO2003022274A3 2-aroylimidazole compounds for treating cancer
07/10/2003WO2003015698A3 Application of lipid vehicles and use for drug delivery
07/10/2003WO2003007880A3 Inhibition of behab cleavage and primary central nervous system (cns) tumors
07/10/2003WO2003004511A3 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
07/10/2003WO2003002765A3 Methods for the diagnosis of cancer based on the obcam and ntm genes
07/10/2003WO2002100354A8 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
07/10/2003WO2002090520A3 Toll/interleukin-1 receptor adaptor protein (tirap)
07/10/2003WO2002083060A3 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
07/10/2003WO2002063008A3 Intracellular signaling molecules
07/10/2003WO2002059326A3 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
07/10/2003WO2002059267A3 Constitutively desensitized g protein-coupled receptors
07/10/2003WO2002046409A3 Proteins and nucleic acids encoding same
07/10/2003WO2002043570A3 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
07/10/2003WO2002028408A9 Compositions and methods for the transport of biologically active agents across cellular barriers
07/10/2003WO2002018581A3 G-protein coupled receptors
07/10/2003WO2002012281A3 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
07/10/2003WO2002000730A9 Pd-l2 molecules: novel pd-1 ligands and uses therefor
07/10/2003WO2001098269A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
07/10/2003WO2001096523A3 Polynucleotides related to colon cancer
07/10/2003WO2001089549A3 Therapeutic uses of il-1 receptor antagonist
07/10/2003US20030131370 Disruption of the glutathione S-transferase-Omega-1 gene
07/10/2003US20030131363 Controlling the activation of genetic translation, cell proliferation, especially hematopoietic cells; drug screening for compounds which alter the activity of the kinase; thalassemias, sickle cell disease, unstable hemoglobins
07/10/2003US20030130523 Delivers more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood; substituted phenylacetanilides containing carboxyl group(s)
07/10/2003US20030130515 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
07/10/2003US20030130505 Nonsteroidal agonists and antagonists
07/10/2003US20030130495 G-protein coupled receptors, signal transduction pathways
07/10/2003US20030130486 A fusion proteins having the C-terminal region of the interfero protein is replaced by a C-terminal region of tau proteins; viricides, antiproliferation agents, antiinflammatory agents; lower cytotoxic side effects